- Home
- CTM vs UNCY Comparison
CTM vs UNCY Comparison
Compare CTM & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTM
- UNCY
- Stock Information
- Founded
- CTM 2019
- UNCY 2016
- Country
- CTM United States
- UNCY United States
- Employees
- CTM N/A
- UNCY N/A
- Industry
- CTM EDP Services
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- CTM Technology
- UNCY Health Care
- Exchange
- CTM Nasdaq
- UNCY Nasdaq
- Market Cap
- CTM 54.7M
- UNCY 58.7M
- IPO Year
- CTM N/A
- UNCY 2021
- Fundamental
- Price
- CTM $1.03
- UNCY $0.55
- Analyst Decision
- CTM
- UNCY Strong Buy
- Analyst Count
- CTM 0
- UNCY 3
- Target Price
- CTM N/A
- UNCY $6.50
- AVG Volume (30 Days)
- CTM 3.8M
- UNCY 929.0K
- Earning Date
- CTM 05-14-2025
- UNCY 05-12-2025
- Dividend Yield
- CTM N/A
- UNCY N/A
- EPS Growth
- CTM N/A
- UNCY N/A
- EPS
- CTM N/A
- UNCY N/A
- Revenue
- CTM $44,764,852.00
- UNCY N/A
- Revenue This Year
- CTM N/A
- UNCY N/A
- Revenue Next Year
- CTM N/A
- UNCY $888.72
- P/E Ratio
- CTM N/A
- UNCY N/A
- Revenue Growth
- CTM N/A
- UNCY N/A
- 52 Week Low
- CTM $0.12
- UNCY $0.20
- 52 Week High
- CTM $2.83
- UNCY $1.60
- Technical
- Relative Strength Index (RSI)
- CTM 45.36
- UNCY 41.12
- Support Level
- CTM $0.98
- UNCY $0.60
- Resistance Level
- CTM $1.08
- UNCY $0.64
- Average True Range (ATR)
- CTM 0.12
- UNCY 0.05
- MACD
- CTM -0.03
- UNCY -0.01
- Stochastic Oscillator
- CTM 16.36
- UNCY 9.86
About CTM Castellum Inc.
Castellum Inc is engaged in providing information technology services. The company provides financial services, healthcare, and other users of large data applications with services that include intelligence analysis, software development, software engineering, program management, strategic and mission planning, information assurance, cybersecurity and policy support, data analytics, and MBSE. In addition to constantly innovating and enhancing organic capabilities, Castellum is acquiring technology companies in the areas of cybersecurity, information technology, electronic warfare, information warfare, and information operations with businesses in the defense, federal, civilian, and commercial markets.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.